HAWTHORNE, N.Y., Feb. 5, 2009 (GLOBE NEWSWIRE) -- Taro Pharmaceutical Industries Ltd. ("Taro," the "Company,") (Pink Sheets:TAROF) reported today that it has received final approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Lamotrigine Tablets (Chewable Dispersible), 5 mg and 25 mg ("lamotrigine chewable tablets").
